Immix Biopharma (IMMX) Other financing activities (2021 - 2026)

Immix Biopharma (IMMX) posted Other financing activities of $33532.0 for Q1 2026, up 1676500.0% sequentially from $2.0 in Q4 2025.

Immix Biopharma (IMMX) Other financing activities (2021 - 2026) Analysis & Trends

Immix Biopharma has reported Other financing activities for 5 years, with the latest figure at $33532.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $33532.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34050.0 (changed N/A YoY) and the FY2025 annual result came in at $6342.0, up 154.8% from the prior year.
Other financing activities climbed to $33532.0 in Q1 2026 per IMMX's latest filing, from $2.0 in the prior quarter.
Over five years, Other financing activities peaked at $175000.0 in Q1 2023 and troughed at -$172382.0 in Q4 2023.
A 4-year average of $6526.2 and a median of $1502.5 in 2024 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 98.58% in 2024, down 98.58% in 2024.
Over 4 years, Other financing activities stood at -$172382.0 in 2023, then soared by 101.44% to $2489.0 in 2024, then plunged by 99.92% to $2.0 in 2025, then surged by 1676500.0% to $33532.0 in 2026.
According to Business Quant data, Other financing activities over the past three periods registered $33532.0, $2.0, and $516.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Immix Biopharma	784.75 Mn	784.75 Mn	-

Download Data